These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21075060)

  • 1. Metabolomic changes in autopsy-confirmed Alzheimer's disease.
    Kaddurah-Daouk R; Rozen S; Matson W; Han X; Hulette CM; Burke JR; Doraiswamy PM; Welsh-Bohmer KA
    Alzheimers Dement; 2011 May; 7(3):309-17. PubMed ID: 21075060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Widely targeted metabolomics of Alzheimer's disease postmortem cerebrospinal fluid based on 9-fluorenylmethyl chloroformate derivatized ultra-high performance liquid chromatography tandem mass spectrometry.
    Muguruma Y; Tsutsui H; Noda T; Akatsu H; Inoue K
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Aug; 1091():53-66. PubMed ID: 29852382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in metabolic pathways and networks in Alzheimer's disease.
    Kaddurah-Daouk R; Zhu H; Sharma S; Bogdanov M; Rozen SG; Matson W; Oki NO; Motsinger-Reif AA; Churchill E; Lei Z; Appleby D; Kling MA; Trojanowski JQ; Doraiswamy PM; Arnold SE;
    Transl Psychiatry; 2013 Apr; 3(4):e244. PubMed ID: 23571809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study.
    Varma VR; Oommen AM; Varma S; Casanova R; An Y; Andrews RM; O'Brien R; Pletnikova O; Troncoso JC; Toledo J; Baillie R; Arnold M; Kastenmueller G; Nho K; Doraiswamy PM; Saykin AJ; Kaddurah-Daouk R; Legido-Quigley C; Thambisetty M
    PLoS Med; 2018 Jan; 15(1):e1002482. PubMed ID: 29370177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic and central nervous system metabolic alterations in Alzheimer's disease.
    van der Velpen V; Teav T; Gallart-Ayala H; Mehl F; Konz I; Clark C; Oikonomidi A; Peyratout G; Henry H; Delorenzi M; Ivanisevic J; Popp J
    Alzheimers Res Ther; 2019 Nov; 11(1):93. PubMed ID: 31779690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive quantification of purine and pyrimidine metabolism in Alzheimer's disease postmortem cerebrospinal fluid by LC-MS/MS with metal-free column.
    Muguruma Y; Tsutsui H; Akatsu H; Inoue K
    Biomed Chromatogr; 2020 Feb; 34(2):e4722. PubMed ID: 31656052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unbiased Metabolomic Investigation of Alzheimer's Disease Brain Points to Dysregulation of Mitochondrial Aspartate Metabolism.
    Paglia G; Stocchero M; Cacciatore S; Lai S; Angel P; Alam MT; Keller M; Ralser M; Astarita G
    J Proteome Res; 2016 Feb; 15(2):608-18. PubMed ID: 26717242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging.
    Motsinger-Reif AA; Zhu H; Kling MA; Matson W; Sharma S; Fiehn O; Reif DM; Appleby DH; Doraiswamy PM; Trojanowski JQ; Kaddurah-Daouk R; Arnold SE
    Acta Neuropathol Commun; 2013 Jun; 1():28. PubMed ID: 24252434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolomics-based promising candidate biomarkers and pathways in Alzheimer's disease.
    Kang J; Lu J; Zhang X
    Pharmazie; 2015 May; 70(5):277-82. PubMed ID: 26062293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics.
    Trushina E; Dutta T; Persson XM; Mielke MM; Petersen RC
    PLoS One; 2013; 8(5):e63644. PubMed ID: 23700429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics.
    Ibáñez C; Simó C; Martín-Álvarez PJ; Kivipelto M; Winblad B; Cedazo-Mínguez A; Cifuentes A
    Anal Chem; 2012 Oct; 84(20):8532-40. PubMed ID: 22967182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysophosphatidylcholine and amide as metabolites for detecting alzheimer disease using ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabonomics.
    Cui Y; Liu X; Wang M; Liu L; Sun X; Ma L; Xie W; Wang C; Tang S; Wang D; Wu Q
    J Neuropathol Exp Neurol; 2014 Oct; 73(10):954-63. PubMed ID: 25192049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolomics Analyses of Saliva Detect Novel Biomarkers of Alzheimer's Disease.
    Huan T; Tran T; Zheng J; Sapkota S; MacDonald SW; Camicioli R; Dixon RA; Li L
    J Alzheimers Dis; 2018; 65(4):1401-1416. PubMed ID: 30175979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Metabolomic and Lipidomic Profiling Reveals Novel Biomarkers of Efficacy for Benfotiamine in Alzheimer's Disease.
    Bhawal R; Fu Q; Anderson ET; Gibson GE; Zhang S
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative metabolomics science in Alzheimer's disease: Relevance and future perspectives.
    Lista S; González-Domínguez R; López-Ortiz S; González-Domínguez Á; Menéndez H; Martín-Hernández J; Lucia A; Emanuele E; Centonze D; Imbimbo BP; Triaca V; Lionetto L; Simmaco M; Cuperlovic-Culf M; Mill J; Li L; Mapstone M; Santos-Lozano A; Nisticò R
    Ageing Res Rev; 2023 Aug; 89():101987. PubMed ID: 37343679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Profiles Help Discriminate Mild Cognitive Impairment from Dementia Stage in Alzheimer's Disease.
    Jääskeläinen O; Hall A; Tiainen M; van Gils M; Lötjönen J; Kangas AJ; Helisalmi S; Pikkarainen M; Hallikainen M; Koivisto A; Hartikainen P; Hiltunen M; Ala-Korpela M; Soininen P; Soininen H; Herukka SK
    J Alzheimers Dis; 2020; 74(1):277-286. PubMed ID: 32007958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation biomarker discovery in Alzheimer's disease using metabolomics - from animal to human studies.
    Hurtado MO; Kohler I; de Lange EC
    Bioanalysis; 2018 Sep; 10(18):1525-1546. PubMed ID: 30198770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood-based diagnosis of Alzheimer's disease using fingerprinting metabolomics based on hydrophilic interaction liquid chromatography with mass spectrometry and multivariate statistical analysis.
    Inoue K; Tsuchiya H; Takayama T; Akatsu H; Hashizume Y; Yamamoto T; Matsukawa N; Toyo'oka T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jan; 974():24-34. PubMed ID: 25463194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Throughput Metabolomics for Discovering Potential Metabolite Biomarkers and Metabolic Mechanism from the APPswe/PS1dE9 Transgenic Model of Alzheimer's Disease.
    Yu J; Kong L; Zhang A; Han Y; Liu Z; Sun H; Liu L; Wang X
    J Proteome Res; 2017 Sep; 16(9):3219-3228. PubMed ID: 28753016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.